发明名称 Cationic lipid
摘要 The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I);(wherein: R1 and R2 are, the same or different, alkenyl, etc, and;X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and;X3 is absent or is alkyl, etc,;Y is absent or anion,;a and b are, the same or different, 0 to 3, and;L3 is a single bond, etc,;R3 is alkyl, etc,;L1 and L2 are —O—, —CO—O— or —O—CO—),;a composition comprising the cationic lipid and a nucleic acid, and;a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like.;
申请公布号 US9408914(B2) 申请公布日期 2016.08.09
申请号 US201113643342 申请日期 2011.04.28
申请人 Kyowa Hakko Kirin Co., Ltd. 发明人 Kuboyama Takeshi;Era Tomohiro;Naoi Tomoyuki
分类号 A61K47/16;A61K47/18;A61K47/22;C07C217/08;C07D211/58;C07C219/06;C07C237/22;C07D491/056;C07C217/28;C07C219/08;C07D207/08;C07D207/12;A61K9/00;A61K9/127;C12N15/113 主分类号 A61K47/16
代理机构 Wenderoth, Lind & Ponack, L.L.P. 代理人 Wenderoth, Lind & Ponack, L.L.P.
主权项 1. A cationic lipid represented by formula (I): wherein: R1 and R2 are, the same or different, each linear or branched alkyl, alkenyl or alkynyl having 12 to 24 carbon atoms, or R1 and R2 are combined together to form dialkylmethylene, dialkenylmethylene, dialkynylmethylene or alkylalkenylmethylene, X1 and X2 are combined together to form a single bond or alkylene, X3 is absent or is alkyl having 1 to 6 carbon atoms, or alkenyl having 3 to 6 carbon atoms, when X3 is absent, Y is absent, a and b are, the same or different, 0 to 3, and are not 0 at the same time, L3 is a single bond, R3 is alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl or morpholinyl, L1 and L2 are, the same or different, —O—, —CO—O— or —O—CO—, orY is absent, a and b are, the same or different, 0 to 3, L3 is —CO— or —CO—O—, R3 is pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl or morpholinyl, wherein at least one of the substituents is amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl or morpholinyl, and L1 and L2 are, the same or different, —O—, —CO—O— or —O—CO—; andwhen X3 is alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms, Y is a pharmaceutically acceptable anion, a and b are, the same or different, 0 to 3, L3 is a single bond, R3 is alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, pyrrolidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl or morpholinyl, L1 and L2 are, the same or different, —O—, —CO—O— or —O—CO—.
地址 Tokyo JP